To NASDAQ OMX Copenhagen A/S
Announcement no. 27-13 / Copenhagen, November 21, 2013
The European patent covering Composition of Matter for belinostat has been granted. The patent will protect belinostat from associated Supplementary Protection Certificates until at least 2021 and possibly until 2026.
The European Patent Office has informed Topotarget that the patent application on Composition of Matter for belinostat (EP01970011) has been granted. This application has claims covering belinostat itself and its use in proliferative diseases including cancer. The ensuing patent will protect the compound until at least 2021, with the possibility of protection up to 2026, from associated Supplementary Protection Certificates. Similar patents have already been granted in other major territories including the US and Japan. The total patent estate covering belinostat compositions, formulations, methods of use, and methods of manufacture cover the clinical use of this drug out to 2030 and beyond.
“This patent allowance equals possibilities. Belinostat is a product with a broad reach and with this grant from the European Patent Office we have secured our product for the next many years”, says Anders Vadsholt, CEO of Topotarget A/S.
About belinostat
Belinostat is a novel pan-HDAC inhibitor in late-stage clinical development with more than 1,100 patients treated. Belinostat has a promising safety profile which allows combination with traditional chemotherapy. Preclinical experiments demonstrated belinostat to be effective against multiple cancers by inhibiting cell proliferation and inducing programed cell death (apoptosis) in tumor cells. Belinostat has been tested in a number of phase I/II clinical trials in hematological cancers and solid tumors both in mono- and combination therapy. Data from these trials have provided evidence of the anti-tumor effect of belinostat, including as monotherapy in peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL), liver cancer, and combination therapy in soft tissue sarcoma (STS) and thymoma.
Topotarget A/S
For further information, please contact:
Anders Vadsholt, CEO – direct: +45 39178345
Background information
About Topotarget
Topotarget (NASDAQ OMX: TOPO) is a Scandinavian-based biopharmaceutical company headquartered in Copenhagen, Denmark, dedicated to clinical development and registration of oncology products. In collaboration with Spectrum Pharmaceuticals, Inc., Topotarget focuses on the development of its lead drug candidate, belinostat, which has shown positive results in the treatment of hematological malignancies and solid tumors, obtained by both mono- and combination therapy. For more information, please refer to www.topotarget.com.
Topotarget Safe Harbor Statement
This announcement may contain forward-looking statements, including statements about Topotarget A/S’ expectations to the progression of Topotarget A/S’ clinical pipeline and with respect to cash burn guidance. Such statements are subject to risks and uncertainties of which many are outside the control of Topotarget A/S, and which could cause actual results to differ materially from those described. Topotarget A/S disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by Danish law.
